Sex Hormones, Oestrogen Receptor, Progesterone Receptor and Human Epithelial Receptor 2 Expressions in Pre and Postmenopausal Sub-Saharan African Women with Breast Cancer

Ajayi, Olulope Olufemi; Charles-Davies, Mabel Ayebatonyo; Anetor, John I.; Ademola, Adeyinka

doi:10.9734/jcti/2016/25259

Cited by 1 publication

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventy-nine non-pregnant women with histologically confirmed breast cancer were recruited into this study, pre-therapy. Enrolment and basic characteristics of the study participants have previously been reported [ 11 ]. Participants were recruited from the Surgical Oncology Clinic of the Department of Surgery, University College Hospital, Ibadan, by a consultant surgical oncologist.…”

Section: Methodsmentioning

confidence: 99%

“…All the premenopausal participants in the study were ER- and PR-negative. Of the study participants, 83.5% presented at advanced stages of the disease (stages 3 and 4), while 16.5% of the study participants presented at stages 1 and 2 [ 11 ].…”

Section: Methodsmentioning

confidence: 99%

“…Breast mitotic rates are highest in the luteal phase of the menstrual cycle [ 6 , 10 ]. Follicle stimulating hormone (FSH) stimulates follicle growth and development in the ovaries and has been associated with certain cancers including breast cancer [ 11 ]. Some reports showed that FSH induces cancer cell proliferation, differentiation, and metastasis by activating adenylyl cyclase, which results in increased cyclic adenosine monophosphate(cAMP) levels [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers

et al. 2018

Self Cite

View full text Add to dashboard Cite

Breast cancer is broadly sub-divided into hormone responsive and non-hormone responsive subtypes. Estradiol has been associated with hormone responsive breast cancers. There is, however, a paucity of information on the role of sex hormones, gonadotropins, and thyroid hormone in non-hormone responsive breast cancer. This study aimed to determine differences in the serum levels of sex hormones, gonadotropins, thyroid hormones, and endocrine disruptors (lead, cadmium, and arsenic) in Nigerian women with hormone responsive and non-hormone responsive breast cancers. Seventy-nine non-pregnant women aged 28–80 years with histologically confirmed breast cancer were recruited, pre-therapy, into this cross-sectional study. They comprised 52 premenopausal women and 27 postmenopausal women recruited from the Surgical Oncology Clinic of the Department of Surgery, University College Hospital, Ibadan. Comparison of biochemical parameters were based on the positivity (+) and negativity (−) of estrogen receptor (ER), progesterone receptor (PR) and human epithelial receptor-2 (HER-2). Estradiol, progesterone, follicle stimulating hormone (FSH), luteinizing hormone (LH), free thyroxine (FT4), free triiodothyronine (FT3), and thyroid stimulating hormone (TSH) were determined using enzyme immunoassay (EIA). Serum lead, cadmium and arsenic were determined using atomic absorption spectrophotometry (AAS). Expression of ER, PR and HER2 were determined using immunohistochemistry. Data was analyzed using Mann-Whitney U-test and multiple regression, with p < 0.05 considered as being statistically significant. Estradiol and progesterone were significantly higher in breast cancer participants with ER− and PR− compared with those with ER+ and PR+ breast cancer (p < 0.05). Follicle stimulating hormone and LH levels were significantly higher in participants with ER+ and PR+ breast cancer compared with participants with ER− and PR− breast cancer (p < 0.05). Arsenic was inversely related with TSH in premenopausal participants with ER− and PR− (β = −0.305; β = −0.304, respectively). Sex hormones and gonadotropins appear to be involved in the pathogenesis of triple negative and luminal breast cancer, respectively.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%